



1617 \$
RECEIVED

JUN 23 2003
PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Castillo et al.

Examiner:

Jiang, S

Serial No.: 10/099,637

Group Art Unit:

1617

Filing Date: 03/15/2002

Attorney Docket No.:

PROTEO.P16CI

Title of Invention: Catechins for the Treatment of Fibrillogenesis in Alzheimer's Disease, Parkinson's Disease, Systemic AA Amyloidosis, and Other Amyloid Disorders

Seattle, Washington 98109
June 17, 2003

COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

In compliance with 37 CFR § 1.56, the references A - FFF listed below and on the attached Information Disclosure Citation are being brought to the Examiner's attention for consideration in connection with the examination of the above-identified patent application.

Per 37 CFR 1.98(d), copies of cited references A - CCC are not enclosed, as those references were cited by or submitted to the office in connection with the prosecution of application Serial No. 09/753,313, filed 12/29/2000, which is relied upon by the present application for priority under 35 U.S.C. Sec. 365; copies of references DDD - FFF are enclosed.

Attached hereto is a check for \$180 to cover the fee for submitting this citation after receipt of the first office action, under 37 CFR 1.97(d). Applicants submit that extra diligence and coordination with the inventors to produce a reasonably comprehensive list of all known closest art required more time than initially anticipated, and then preparation for submission of this citations was further delayed for funding reasons and therefore not completed until after the date of the 04/08/2003 office action.

Applicant and their attorney submit that the references cited herein taken alone or in combination neither anticipate nor render obvious the present invention. The listed references

06/20/2003 WASFAW1 00000088 10099637

01 FC:1806

180.00 DP

CERTIFICATE OF MAILING (37 CFR 1.8A)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, PO Box 1450, Alexandria, VA 22313-1450.

Patrick Dwyer


June 17, 2003

1-8PCRT.INS


relate to the general field of the disclosure and these citations do not constitute an admission that the references are relevant or material to the claims; they are cited only as constituting the closest art of which the Applicant is aware.

OTHER REFERENCES


Ex.	Doc #	Description (Author, Title, Date, Pertinent Pages, Etc.)
	A	SUGITA-KONISHI et al. "Epigallocatechin Gallate and Gallocatechin Gallate in Green Tea Catechins Inhibit Extracellular Release of Vero Toxin from Enterohemorrhagic <i>Escherichia coli</i> O157:H7", <i>Biochimica et Biophysica Acta</i> 1472, pp.42-50, 1999.
	B	GEJYO et al. "A New Form of Amyloid Protein Associated with Chronic Hemodialysis was Identified as β 2-Microglobulin" <i>Biochemical and Biophysical Research Communications</i> , Vol. 129. No.3. pp.701-706. June 28, 1985.
	C	GEJYO et al. " β 2-microglobulin: A new form of amyloid protein associated with chronic hemodialysis," <i>Kidney International</i> , Vol. 30. pp.385-390, 1986.
	D	SARAIVA et al. "Studies on plasma transthyretin (Prealbumin) in familial Amyloidotic Polyneuropathy, Portuguese type", <i>J. Lab. Clin. Medicine</i> , Vol. 102, No.4, pp.590- 603. October 1983.
	E	SARAIVA et al. "Amyloid fibril protein in Familial Amyloidotic Polyneuropathy, Portuguese Type", <i>J. Clin. Invest.</i> Vol. 74. pp.104-119, July 1984.
	F	TAWARA et al. "Amyloid fibril protein in type I Familial Amyloidotic Polyneuropathy in Japanese, <i>J. lab. Clin. Med.</i> pp.811-822. December. 1981.
	G	JOHNSON et al. "Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus, <i>The New England Journal of Medicine</i> , Vol. 321. No.8, pp.513-518, Aug. 24, 1989.
	H	HARADA et al. "Human Amyloid Protein: Chemical Variability and Homogeneity", <i>The Journal of Histochemistry and Cytochemistry</i> , Vol. 19, No. 1. pp.1-15. June 30, 1970.
	I	MADIAS et al. "Familial Mediterranean Fever and Amyloidosis, <i>Kidney International</i> , Vol. 20, pp.676-685, 1981.
	J	BENSON et al. "Serum Amyloid A Protein in Amyloidosis, Rheumatic, and Neoplastic Diseases, <i>Arthritis and Rheumatism</i> , Vol. 22, No.1 pp.36-42. January, 1979.
	K	KAMEI et al. "Amyloidosis Associated with Juvenile Rheumatoid Arthritis, <i>Acta Pathol. Jpn.</i> Vol. 32. No.1, pp.123-133. 1982.
	L	PUCHTLER et al. "On the Binding of Congo Red by Amyloid, <i>J. Histochem. Cytochem.</i> Vol. 10, pp.355-364. Sept. 27, 1975.
	M	McADAM et al. "Association of Amyloidosis with Erythema Nodosum Leprosus Reactions and Recurrent Neutrophil Leucocytosis Leprosy", <i>The Lancet</i> , pp. 572-575. September 27, 1975.



N	GLENNER et al. "Alzheimer Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, Vol. 120, No.3, pp.885-890, May 16, 1984.
	HASHIMOTO et al. "Human Recombinant NACP/ α -synuclein is Aggregated and Fibrillated in vitro: Relevance for Lewy Body Disease," Brain Research, Vol. 799, pp.301-306, 1998.
P	PONTE et al. "A new A4 amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," Nature, Vol. 331, pp. 525-527. Feb. 11, 1988.
Q	WHO-IUIS Nomenclature Sub-Committee "Nomenclature of Amyloid and Amyloidosis," Bulletin of the World Health Organization, Vol. 71, No.1, pp.105-108, 1993.
R	MASTERS et al. "Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome," Medical Sciences, Vol. 82, pp.4245-4249. June 1985.
S	KITAGUCHI et al. "Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity," Nature Vol. 331, pp.530-532. Feb. 1988.
T	TANZI et al. "Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease," Nature, Vol. 331. pp.528-530. Feb. 1988.
U	PARDRIDGE et al. "Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-dalton Peptide Isolated from Cortical Microvessels," Journal of Neurochemistry, Vol. 49, No.5, pp.1394-1401. 1987.
V	MANDYBUR et al. "Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications," Journal of Neuropathology and Experimental Neurology, Vol. 45, No. 1, pp.79-90, Jan. 1986.
W	PIKE et al. "Structure-activity Analyses of β -Amyloid Peptides: Contributions of the β 25-35 Region to Aggregation and Neurotoxicity," Journal of Neurochemistry, Vol. 64, pp.253-265, 1995.
X	PIKE et al. "In Vitro Aging of β -amyloid protein causes peptide aggregation and neurotoxicity," Brain Research, Vol. 563, pp.311-314, 1991.
Y	GAMES et al. "Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F β -amyloid Precursor Protein," Nature, Vol. 373. pp.523-537. Feb. 9, 1995.
Z	HARRIGAN et al., "Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures," Neurobiology of Aging, Vol. 16, No.5, pp.779-789. 1995.
AA	HAASS et al, "The Swedish Mutation Causes Early-onset Alzheimer's Disease by β -secretase Cleavage within the Secretory Pathway," Nature Medicine, Vol. 1, No.12, pp.1291-1296, 1995.
BB	BROECKHOVEN et al, "Amyloid β Protein Precursor Gene and Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch)" Science, Vol. 248. pp.1120-1121. June. 1990.
CC	MURRELL et al, "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease," Science, Vol. 25, pp.97-99. Oct.. 4, 1991.
DD	FLOOD et al., "An Amyloid β -protein Fragment, A β [12-28], Equipotently Impairs Post-training Memory Processing When Injected into Different Limbic System Structures," Brain Research Vol. 663, pp.271-276. 1994.



EE	FLOOD et al., "Amnestic Effects in Mice of Four Synthetic Peptides Homologous to Amyloid β -protein From Patients with Alzheimer's Disease," Proc. Natl. Acad. Sci. Vol.88, pp.3363-3366. 1991.
FF	POLYMEROPOULOS et al., "Mutation in the α -synuclein Gene Identified in Families with Parkinson's Disease," Science Vol. 276. pp.2045-2047. June 27, 1997.
GG	SPILLANTINI et al., " α -Synuclein in Filamentous Inclusions of Lewy Bodies from Parkinson's Disease and Dementia with Lewy bodies," Proc. Natl. Acad. Sci. Vol. 95, pp.6469-7473, May 1998.
HH	WOOD et al. " α -Synuclein Fibrillogenesis is Nucleation-dependent," The Journal of Biological Chemistry, Vol. 274, No.28, pp.19509-19512, Jul. 1999.
II	UEDA et al. "Molecular Cloning of cDNA Encoding an Unrecognized Component of Amyloid in Alzheimer Disease," Proc. Natl. Acad. Sci. Vol. 90, pp.11282-11286, Dec.1993.
JJ	KRUGER et al. "Ala30 Pro mutation in the Gene Encoding α -synuclein in Parkinson's Disease," Nature Genetics, Vol. 18, pp.106-108, Feb.18,1988.
KK	KLUNK et al. "Quantifying Amyloid β -peptide ($A\beta$) Aggregation Using the Congo red- $A\beta$ (Cr- $A\beta$) Spectrophotometric Assay," Analytical Biochemistry, Vol. 266, pp.66-76, 1999.
LL	CONWAY et al. "Accelerated in Vitro Fibril Formation by a Mutant α -synuclein Linked to Early-onset Parkinson Disease," Nature Medicine, Vol. 4. No.11, pp.318-320. Sept. 1998.
MM	NAIKI et al. "Kinetic Analysis of Amyloid Fibril Polymerization in Vitro," Laboratory Investigation, Vol. 65, No.1, pp.104-110, 1991.
NN	NAIKI et al. "First-order Kinetic Model of Alzheimer's β -amyloid Fibril Extension in vitro," Laboratory Investigation, Vol. 74, No.2. pp.374-383, Feb. 1996.
OO	ARAI et al. "Argyrophilic Glial Inclusions in the Midbrain of Patients with Parkinson's Disease and Diffuse Lewy Body Disease are Immunopositive for NACP/ α -synuclein," Neuroscience Letters, Vol. 259, pp.83-86, 1999.
PP	POLLANEN et al. "Pathology and Biology of the Lewy body," Journal of Neuropahtology and Experimental Neurology, Vol. 52, No.3, pp.183-191, May, 1993.
QQ	HSIAO et al. "Correlative Memory Deficits, $A\beta$ elevation and Amyloid Plaques in Transgenic Mice," Science, Vol. 274, pp.99-102. Oct. 4, 1996.
RR	NARHI et al. "Both Familial Parkinson's Disease Mutations Accelerate α -Synuclein Aggregation," Vol. 274, No.14, pp.9843-9846, Apr. 1999.
SS	LEVINE III et al. "Thioflavine T interaction with Synthetic Alzheimer's Disease β -amyloid Peptides: Detection of Amyloid Aggregation in Solution," Protein Science, Vol. 2, pp.404-410, 1993.
TT	VIRGINIA et al. "A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau," Science, Vol. 251. pp.675-678. Feb. 1991.
UU	KOSIK et al. "Microtubule-associated Protein tau () is a Major Antigenic Component of Paired Helical Filaments in Alzheimer Disease," Proc. Natl. Acad. Sci, Vol. 83, pp.4044-4048, Jun. 1986.
VV	GRUNDKE-IQBAL et al. "Abnormal Phosphorylation of the Microtubule-Associated Protein (tau) in Alzheimer Cytoskeletal Pathology," Proc. Natl. Acad. Sci. Vol. 83, pp.4913-4917, Jul. 1986.



WW	CUTLER et al. "Tacrine in Alzheimer's Disease," The New England Journal of Medicine," Vol. 328, No.11, pp.808-810, Mar. 18, 1993.
XX	HARDY et al. "Framing β -amyloid," Nature Genetics Vol. 1, pp.233-234, Jul. 1992.
YY	CASTILLO et al. "Perlecan Binds to the β -Amyloid Proteins ($A\beta$) of Alzheimer's Disease, Accelerates $A\beta$ Fibril Formation, and Maintains $A\beta$ Fibril Stability," Journal of Neurochemistry, Vol. 69, pp.2452-2465, 1997.
ZZ	BARNER et al. "Donepezil use in Alzheimer disease," The Annals of Pharmacotherapy, Vol. 32, pp.70-77, Jan. 1998.
AAA	LeVINE III et al. "Thioflavine T interaction with Amyloid β -sheet Structures," Amyloid Intl. Exp. Clin. Invest. Vol. 2, pp.1-6, 1995.
BBB	SHIN-YA et al. "Antioxidant Protects the Nervous System Diminishing β -amyloid Peptide Toxicity by Catechin," Kagaku to Seibutsu (Chemistry and Biology), Vol. 38, No. 4, 212-214, 2000. (Not translated.)
CCC	Mitsui Norin Japanese Patent No. 10245342 (Not translated.)
DDD	Mitsui Norin Japanese Patent No. 10245342 (Translation.)
EEE	SHIN-YA et al. "Antioxidant Protects the Nervous System Diminishing β -amyloid Peptide Toxicity by Catechin," Kagaku to Seibutsu (Chemistry and Biology), Vol. 38, No. 4, 212-214, 2000. (Translation.)
FFF	Wirth et al. "Pharmacologically Active Procyanidines from the Bark of Uncaria tomentosa", Phytomedicine, Vol. 4 (3), pp. 265-266, 1997.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached Information Disclosure Citation with initials or other appropriate marks.

Tel. No. (206) 343-7074
P16CI-IDS.DOC

Respectfully submitted,

PATRICK MICHAEL DWYER
Reg. No. 32,411

PATRICK M. DWYER
PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109

RECEIVED
JUN 23 2003
TECH CENTER 1600/2900